CD69 and melanoma: Surprisingly, the expression of T‐cell activation markers (CD25 and CD69) on Jurkat T cells cocultured with IFN‐γ or IFN‐γ + vemurafenib‐pretreated melanoma cells remained unchanged (Fig. S3), indicating that either the magnitude of PD‐L1 downregulation is insufficient to alleviate T‐cell exhaustion or the decreased expression of PDL1 on melanoma cells treated with vemurafenib is compensated by an increased level of a different checkpoint/immunoregulatory molecule.